

- in the removal of non-transferrin-bound iron (NTBI). *Blood* 1998; 92(Suppl.):668.
24. Franchini M, Gandini G, de Gironcoli M, Vassanelli A, Borgna-Pignatti C, Aprili G. Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload. *Blood* 2000; 95:2776-9.
 25. Olivieri NF, Nisbet-Brown E, Srichaitanakool S, et al. Studies of iron excretion and non-transferrin-bound plasma iron following a single infusion of hydroxyethyl starch-deferoxamine: a new approach to iron chelation therapy. *Blood* 1996; 88 (Suppl.):310a.
 26. Porter JB, Wier DT, Davis B, et al. Iron balance and chelation efficacy following single dose depot desferrioxamine. *Blood* 1998; 92 (Suppl.):325.
 27. Galanello R, Kattamis C, Athanassiou M, et al. A depot formulation of desferrioxamine (ICL749B): update on the dose-finding program. *Blood* 1999; 94(Suppl.):30.
 28. Hoffbrand AV. Oral iron chelation. *Semin Hematol* 1996; 33:1-8.
 29. Barman Balfour JA, Foster RH. Deferiprone. A review of its clinical potential in iron overload in thalassemia major and other transfusion-dependent diseases. *Drugs* 1999; 58:553-78.
 30. Mazza P, Amurri B, Lazzari G, et al. Oral iron chelating therapy. A single center interim report on deferiprone (L1) in thalassemia. *Haematologica* 1998; 83: 496-501.
 31. Rombos Y, Tzanetea R, Konstantopoulos K, et al. Chelation therapy in patients with thalassemia using the orally active iron chelator deferiprone (L1). *Haematologica* 2000; 85:115-7.
 32. Maggio A, Capra M, Ciaccio C, et al. Evaluation of efficacy of L1 versus desferrioxamine by clinical randomized multicentric study. *Blood* 1999; 94 (Suppl.):34.
 33. Longo F, Fischer R, Engelhardt R, Nielsen P, Sacchetti L, Piga A. Iron balance in thalassemia patients treated with deferiprone. *Blood* 1998; 92 (Suppl.):325.
 34. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. *N Engl J Med* 1998; 339:417-23.
 35. Berdoukas VA, Lindeman R, Eagle C, et al. Liver assessment in a group of transfusion dependent patients treated with deferiprone and compared to a group of patients treated with desferrioxamine. *Blood* 1999; 94 (Suppl.):30b.
 36. Wonke B, Telfer P, Hoffbrand AV. Iron chelation with oral deferiprone in patients with thalassemia. *N Engl J Med* 1998; 339:1712.
 37. Grady RW, Giardina PJ. Iron chelation with oral deferiprone in patients with thalassemia. *N Engl J Med* 1998; 339:1712-3.
 38. Addis A, Lochstein R, Koren G, Einarson TR. Meta-analytic review of the clinical effectiveness of oral deferiprone (L1). *Eur J Clin Pharmacol* 1999; 55:1-6.
 39. Mangiagli A, de Sanctis V, Campisi S, Di Silvestro G, Gamberini RM. Long-term follow up of growth, bone and cartilage abnormalities during chelation therapy with deferoxamine and deferiprone. *Blood* 1999; 94 (Suppl.):34b.
 40. Olivieri NF, Brittenham GM. Evidence of progression of myocardial iron loading as determined by magnetic resonance imaging (MRI) in thalassemia patients during treatment with deferiprone (L1) and deferoxamine (DFO). *Blood* 1999; 94 (Suppl.):35b.

Antitumor vaccination

Several studies are currently evaluating the efficacy and safety of tumor-specific vaccination strategies in cancer patients. In this issue of *Haematologica*, Bocchia et al report an extensive review on this exciting subject. Other papers on this topic have been published in recent years.¹⁻⁸

References

1. Stevenson FK, King CA, Spellerberg MB, Zhu D, Rice J, Sahota S, Thompsett A, Radl J, Hamblin TJ. DNA vaccines against haematological malignancies. *Haematologica* 1999; 84(EHA4 Educational Book): 11-3.
2. Coiffier B. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma patients. *Haematologica* 1999; 84(EHA4 Educational Book):14-8.
3. Cotter FE. Antisense oligonucleotides for haematological malignancies. *Haematologica* 1999; 84(EHA4 Educational Book):19-22.
4. Lanzavecchia A. Dendritic cell maturation and generation of immune responses. *Haematologica* 1999; 84(EHA4 Educational Book):23-5.
5. Melief CJ, Schoenberger S, Toes R, Offringa R. Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells. *Haematologica* 1999; 84(EHA4 Educational Book):26-7.
6. Sallusto F. The role of chemokines and chemokine receptors in T cell priming and Th1/Th2-mediated responses. *Haematologica* 1999; 84(EHA4 Educational Book):28-31.
7. Bordignon C, Carlo-Stella C, Colombo MP, et al. Cell therapy: achievements and perspectives. *Haematologica* 1999; 84:1110-49.
8. Aglietta M, Bertolini F, Carlo-Stella C, et al. Ex vivo expansion of hematopoietic cells and their clinical use. *Haematologica* 1998; 83:824-48.